Theragnostics is a radiopharmaceutical company whose mission is to improve the lives of cancer patients with novel agents for molecular imaging and therapy.
@Theragnostics is delighted to announce the appointments of key drug development experts Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to our Board as we prepare for the next stage of growth.
Read more: https://t.co/FyXoQdsIOo
#biotech#oncology#cancer
Great to see increasing interest in the next generation of radiopharmaceuticals” with a link to this article? RayzeBio debuts with $45M to target tumors with radiopharmaceuticals: https://t.co/v4ysvxIxR4
We are proud to support #OvarianCancerAwarenessMonth as we continue to work on the development of our targeted #radionuclide THG-009. Spotting signs and symptoms earlier is crucial. @OvarianCancerUK explains what you should be looking out for:
https://t.co/1DdVIeXBij
Theragnostics is proud to announce our collaboration with the ‘Next generation molecular imaging and therapy with radionuclide’ (MITHRAS) programme currently launching in the UK.
https://t.co/zyvivLiX0O
@Theragnostics
CEO Greg Mullen will be attending the Prostate Cancer PSMA Masterclass this week at @ExploreWelcome in partnership with @UCL.
More information: https://t.co/7defCCjWnH
Register here: https://t.co/yfW4DyETfi
#radiopharmaceuticals#oncology#WellcomeTrust#PSMA
We are working hard to develop and perfect our single step cold kit Prostate Cancer Diagnostic, #PSMA. We strive to reach more people by making Prostate Diagnostic Imaging more accessible . See how at
https://t.co/HzaSFqaDtn
Theragnostics would like to say thanks to our Director of Project Management and Business Development, Aaron Block, for showing his support for #prostatecancerawarenessmonth with an impressive mustache. #Movember
#Theragnostics strengthens leadership team with two key appointments: Chris Sterling appointed as Non-Executive Director. #Radiopharmaceutical#drugdevelopment expert Dr Daniel Stevens joins as Chief Medical Officer
https://t.co/OBZNFH0gQN
18F-PARPi Phase I trial data in head & neck cancer goes into the public domain. Just the beginning for rPARPi. #Theragnostics#rPARPi#Clinicaltrials
https://t.co/JsLZAceuL7
Fantastic news from our friends at @Theragnostics who have partnered with @GEHealthcare for late stage PSMA diagnostic for #ProstateCancer There novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment. Great collab.